X9cad7a78.ea9b.47b0.9d06.e5e696031cc3
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 74
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYOGENESIS+0.490
- KRAS_SIGNALING_DN+0.420
- NOTCH_SIGNALING+0.390
- HEDGEHOG_SIGNALING+0.340
- COAGULATION+0.330
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.320
- APICAL_JUNCTION+0.290
- APICAL_SURFACE+0.260
- ESTROGEN_RESPONSE_EARLY+0.240
- ANGIOGENESIS+0.220
Top 10 suppressed
- E2F_TARGETS-0.670
- G2M_CHECKPOINT-0.640
- MYC_TARGETS_V1-0.640
- MYC_TARGETS_V2-0.580
- UNFOLDED_PROTEIN_RESPONSE-0.550
- MTORC1_SIGNALING-0.540
- OXIDATIVE_PHOSPHORYLATION-0.520
- PROTEIN_SECRETION-0.520
- INTERFERON_ALPHA_RESPONSE-0.510
- DNA_REPAIR-0.490
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | s0095205 | — | — | 0.939 |
| 2 | s0122297 | — | — | 0.911 |
| 3 | SRR9879289 | — | cohortSQ1 | 0.909 |
| 4 | R116 | — | — | 0.909 |
| 5 | TCGA-AC-A3W7-01A-11R-A22K-07 | — | A | 0.907 |
| 6 | TCGA-BH-A28O-01A-11R-A22K-07 | — | A | 0.905 |
| 7 | SRR4296064 | — | cohortA1 | 0.904 |
| 8 | MNG768 | — | — | 0.903 |
| 9 | TCGA-ZF-A9R9-01A-11R-A38B-07 | — | — | 0.902 |
| 10 | TCGA-HN-A2OB-01A-21R-A27Q-07 | — | A | 0.900 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYOGENESIS | 0.490 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.420 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.390 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.340 | Inavolisib | — uncovered |
| COAGULATION | 0.330 | Binimetinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.320 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.290 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.260 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.240 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.220 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.200 | Cobimetinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.190 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.130 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.130 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.110 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.110 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.100 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.080 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.060 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.040 | Inavolisib | — uncovered |